Literature DB >> 2550281

Interactions of formylmethionyl-leucyl-phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes. Effects on superoxide release, inositol phosphates and cAMP.

K R Elliott1, E J Leonard.   

Abstract

Cessation of the fMLF-induced burst of human monocyte superoxide release was associated with a rise in cAMP. This was not due to inhibition of phosphodiesterase (PDE), the major form of which was the PDE IV isozyme. The action of burst inhibitors did not correlate with cAMP levels: Rolipram, a PDe IV inhibitor, increased cAMP 6-fold, with minimal effects on the burst; whereas theophylline increased cAMP less than 2-fold but decreased the burst to less than half. Although theophylline and the adenylate cyclase activator, adenosine, inhibited fMLF-induced superoxide release, they did not inhibit production of inositol phosphates. Thus, these studies on inhibition of superoxide release implicated neither cAMP nor inositol phosphates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550281     DOI: 10.1016/0014-5793(89)81016-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

Authors:  K H Banner; E Moriggi; B Da Ros; G Schioppacassi; C Semeraro; C P Page
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.

Authors:  G Dent; M A Giembycz; K F Rabe; P J Barnes
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

3.  The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.

Authors:  N C Turner; L J Wood; F M Burns; T Gueremy; J E Souness
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.